Search results for "Agoni"

showing 10 items of 2493 documents

The Transcription Factor T-bet Is Induced by IL-15 and Thymic Agonist Selection and Controls CD8αα+ Intraepithelial Lymphocyte Development

2014

Summary CD8αα + intraepithelial lymphocytes (IELs) are instrumental in maintaining the epithelial barrier in the intestine. Similar to natural killer cells and other innate lymphoid cells, CD8αα + IELs constitutively express the T-box transcription factor T-bet. However, the precise role of T-bet for the differentiation or function of IELs is unknown. Here we show that mice genetically deficient for T-bet lacked both TCRαβ + and TCRγδ + CD8αα + IELs and thus are more susceptible to chemically induced colitis. Although T-bet was induced in thymic IEL precursors (IELPs) as a result of agonist selection and interleukin-15 (IL-15) receptor signaling, it was dispensable for the generation of IEL…

AgonistCD4-Positive T-Lymphocytesmedicine.drug_classCD8 AntigensReceptors Antigen T-Cell alpha-betaImmunologychemical and pharmacologic phenomenaBiologyCD8-Positive T-Lymphocytesdigestive systemMiceTRANSCRIPTION FACTOR TmedicineTranscriptional regulationImmunology and AllergyAnimalsIntestinal MucosaTranscription factorInterleukin-15Mice KnockoutReceptors Interleukin-15Innate lymphoid cellCell DifferentiationEpithelial CellsReceptors Antigen T-Cell gamma-deltahemic and immune systemsColitisCell biologyIntestinesMice Inbred C57BLInfectious DiseasesInterleukin 15ImmunologyIntraepithelial lymphocyteT-Box Domain ProteinstissuesFunction (biology)Signal TransductionImmunity
researchProduct

Synthesis and evaluation of zirconium-89 labelled and long-lived GLP-1 receptor agonists for PET imaging

2020

Contains fulltext : 220838.pdf (Publisher’s version ) (Open Access) INTRODUCTION: Lately, zirconium-89 has shown great promise as a radionuclide for PET applications of long circulating biomolecules. Here, the design and synthesis of protracted and long-lived GLP-1 receptor agonists conjugated to desferrioxamine and labelled with zirconium-89 is presented with the purpose of studying their in vivo distribution by PET imaging. The labelled conjugates were evaluated and compared to a non-labelled GLP-1 receptor agonist in both in vitro and in vivo assays to certify that the modification did not significantly alter the peptides' structure or function. Finally, the zirconium-89 labelled peptide…

AgonistCancer ResearchBiodistributionmedicine.drug_class[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/ImagingPeptide[CHIM.THER]Chemical Sciences/Medicinal Chemistry[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineChemistry Techniques SyntheticPharmacologyRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]Glucagon-Like Peptide-1 Receptor030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineIn vivomedicineRadiology Nuclear Medicine and imagingTissue DistributionAmino Acid SequenceReceptorGlucagon-like peptide 1 receptorchemistry.chemical_classificationRadioisotopesRadiochemistryChemistryIn vitro toxicology030220 oncology & carcinogenesisDrug DesignIsotope LabelingPositron-Emission Tomography[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyMolecular MedicineZirconiumPeptidesNanomedicine Radboud Institute for Molecular Life Sciences [Radboudumc 19]Ex vivoHalf-Life
researchProduct

Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors.

2021

Simple Summary The clinical efficacy of immunotherapies when treating cold tumors is still low, and different treatment combinations are needed when dealing with this challenging scenario. In this work, a middle-out strategy was followed to develop a model describing the antitumor efficacy of different immune-modulator combinations, including an antigen, a toll-like receptor-3 agonist, and an immune checkpoint inhibitor in mice treated with non-inflamed tumor cells. Our results support that clinical response requires antigen-presenting cell activation and also relies on the amount of CD8 T cells and tumor resistance mechanisms present. This mathematical model is a very useful platform to ev…

AgonistCancer ResearchProgrammed cell deathmedicine.drug_classmedicine.medical_treatmentcold tumorscombination of therapeuticsArticleAntigenmedicinepreclinicalDoubling timeimmuno-oncologyRC254-282biologybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapydrug developmentmechanistic modelingOncologyDrug developmentCancer researchbiology.proteinAntibodybusinessCD8Cancers
researchProduct

Dopaminergic modulation of low-Mg2+-induced epileptiform activity in the intact hippocampus of the newborn mouse in vitro

2012

To investigate whether epileptiform activity in the immature brain is modulated by dopamine, we examined the effects of dopaminergic agonists and antagonists in an intact in vitro preparation of the isolated corticohippocampal formation of immature (postnatal days 3 and 4) C57/Bl6 mice using field potential recordings from CA3. Epileptiform discharges were induced by a reduction of the extracellular Mg(2+) concentration to 0.2 mM. These experiments revealed that low concentrations of dopamine ( 3 μM dopamine enhanced epileptiform activity. The D1-agonist SKF38393 (10 μM) had a strong proconvulsive effect, and the D2-like agonist quinpirole (10 μM) mediated a weak anticonvulsive effect. The …

AgonistChemistrymedicine.drug_classAntagonistPharmacologyReceptor antagonistCellular and Molecular NeuroscienceQuinpiroleDopamine receptorDopamine receptor D3DopaminemedicineSulpiridemedicine.drugJournal of Neuroscience Research
researchProduct

Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol

2015

Abstract Long-acting β 2 -adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low β 2 -adrenoceptors availability, like in inflamed airways, a full agonist can maintain its b…

AgonistChronic ObstructiveIntrinsic activitymedicine.drug_classSocio-culturaleLABASettore MED/10 - Malattie Dell'Apparato RespiratorioPharmacologyPartial agonistPulmonary DiseaseAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Internal MedicinePulmonary Disease Chronic Obstructiveimmune system diseasesFormoterol FumarateInternal MedicinemedicineHumansFormoterolSalmeterolSalmeterol XinafoateBronchodilator AgentAsthmaCOPDbusiness.industryChronic obstructive pulmonary diseaseMedicine (all)Asthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterolrespiratory systemmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeAnesthesiaFormoterolOnset of actionSalmeterolbusinessAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Bronchodilator Agents; Formoterol Fumarate; Humans; Pulmonary Disease Chronic Obstructive; Salmeterol Xinafoate; Treatment Outcome; Internal MedicineHumanmedicine.drugEuropean Journal of Internal Medicine
researchProduct

Induction of apoptosis in cardiac myocytes by an A3 adenosine receptor agonist.

1998

The effects of the selective adenosine (ADO) A3 receptor agonist IB-MECA (N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide) on cultured newborn rat cardiomyocytes were examined in comparison with ADO, the ADO A1 receptor-selective agonist R-PIA (N6-R-phenylisopropyladenosine), or the ADO A3 selective antagonist MRS 1191 (3-ethyl-5-benzyl-2-methyl-6-phenyl-4-phenylethynyl-1, 4-(+/-)-dihydropyridine-3,5 dicarboxylate), using digital image analysis of Feulgen-stained nuclei. At high concentration, IB-MECA (/=10 microM ) and ADO (200 microM) induced apoptosis; however, R-PIA or MRS 1191 did not have any detectable effects on cardiac cells. In addition, DNA breaks in cardiomyocytes undergoing a…

AgonistContraction (grammar)TUNEL assayAdenosinemedicine.drug_classMyocardiumReceptor Adenosine A3ApoptosisHeartCell BiologyDNA FragmentationBiologyAdenosine receptorMolecular biologyAdenosineRatsApoptosismedicinePurinergic P1 Receptor AgonistsMyocyteAnimalsCalciumReceptorCells Culturedmedicine.drugExperimental cell research
researchProduct

Synthesis and Characterization of a Novel Series of Agonist Compounds as Potential Radiopharmaceuticals for Imaging Dopamine D-2/3 Receptors in Their…

2014

Imaging of dopamine D2/3 receptors (D2/3R) can shed light on the nature of several neuropsychiatric disorders in which dysregulation of D2/3R signaling is involved. Agonist D2/3 tracers for PET/SPECT imaging are considered to be superior to antagonists because they are more sensitive to dopamine concentrations and may selectively label the high-affinity receptor state. Carbon-11-labeled D2/3R agonists have been developed, but these short-lived tracers can be used only in centers with a cyclotron. Here, we report the development of a series of novel D2R agonist compounds based on the 2-aminomethylchromane (AMC) scaffold that provides ample opportunities for the introduction of longer-lived […

AgonistD-3 RECEPTORPHARMACOPHOREChemistrymedicine.drug_classDERIVATIVESPharmacologyIN-VIVO ACTIVITYHUMAN BRAINRadioligand AssayANTERIOR-PITUITARYPOSITRON-EMISSION-TOMOGRAPHYENDOGENOUS DOPAMINEIn vivoDopamineSpect imagingDopamine receptor D2Drug DiscoveryLIGAND-BINDINGmedicineMolecular MedicineReceptorAGENTSEndogenous agonistmedicine.drugJournal of Medicinal Chemistry
researchProduct

Inhibition of human detrusor contraction by a urothelium derived factor.

2003

Stimulating muscarinic receptors in pig bladder urothelium causes the release of a diffusable factor that inhibits contractions of the underlying detrusor muscle. We investigated whether the contractions of human detrusor strips elicited by the muscarinic agonist carbachol, electrical field stimulation, KCl or the neurokinin receptor agonist neurokinin A are affected by the urothelium.Paired intact and urothelium denuded muscle strips were placed in modified gassed Tyrode's solution at 37C. Cumulative concentration-response curves to carbachol or KCl were constructed. In other tissues the strips were stimulated electrically (1 to 40 Hz) with trains of square wave pulses 20 seconds in durati…

AgonistDetrusor muscleMalemedicine.medical_specialtyCarbacholmedicine.drug_classUrologyNeurokinin APig bladderMuscarinic Agonistsurologic and male genital diseasesMuscarinic agonistPotassium Chloridechemistry.chemical_compoundInternal medicineCulture TechniquesMuscle HypertoniamedicineHumansUrotheliumAgedDose-Response Relationship Drugurogenital systembusiness.industryTissue ExtractsMuscle SmoothMiddle Agedfemale genital diseases and pregnancy complicationsElectric StimulationStimulation ChemicalEndocrinologymedicine.anatomical_structurechemistryCarbacholFemaleNeurokinin Amedicine.symptomUrotheliumbusinessmedicine.drugMuscle contractionMuscle ContractionThe Journal of urology
researchProduct

Human oxytocin receptors in cholesterol-rich vs. cholesterol-poor microdomains of the plasma membrane

2000

We analyzed the properties of a G protein-coupled receptor localized in cholesterol-poor vs. cholesterol-rich microdomains of the plasma membrane. For this purpose, the human oxytocin receptor, which is very sensitive against alterations of the membrane cholesterol level, was stably expressed in HEK293 cells. To calculate the total number of receptors independent of ligand binding studies, the oxytocin receptor was tagged with an enhanced green fluorescent protein (EGFP) which did not change the functional properties of the receptor. Only 1% of the oxytocin receptors were present in cholesterol-rich detergent-insoluble domains. In contrast, employing a detergent-free fractionation scheme th…

AgonistGTP'medicine.drug_classPlasma protein bindingBiologyBiochemistryOxytocin receptorReceptor–ligand kineticsMembraneBiochemistryCaveolaeBiophysicsmedicineReceptorEuropean Journal of Biochemistry
researchProduct

Neuronal nicotinic receptors in synaptic functions in humans and rats: physiological and clinical relevance.

2000

The present report describes the participation of nicotinic receptors (nAChRs) in controlling the excitability of local neuronal circuitries in the rat hippocampus and in the human cerebral cortex. The patch-clamp technique was used to record responses triggered by the non-selective agonist ACh and the alpha7-nAChR-selective agonist choline in interneurons of human cerebral cortical and rat hippocampal slices. Evidence is provided that functional alpha7- and alpha4beta2-like nAChRs are present on somatodendritic and/or preterminal/terminal regions of interneurons in the CA1 field of the rat hippocampus and in the human cerebral cortex and that activation of the different nAChR subtypes pres…

AgonistInterneuronmedicine.drug_classCentral nervous systemHippocampusBiologyHippocampal formationReceptors NicotinicHippocampusSynaptic TransmissionMembrane PotentialsRats Sprague-DawleyBehavioral NeuroscienceAlzheimer DiseaseInterneuronsCulture Techniquesmental disordersmedicineAnimalsHumansReceptorgamma-Aminobutyric AcidCerebral CortexNeuronsBrain Mappingmusculoskeletal neural and ocular physiologyBrainRatsmedicine.anatomical_structurenervous systemCerebral cortexSchizophreniasense organsNeuroscienceAcetylcholinemedicine.drugBehavioural brain research
researchProduct